Study of Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of the Alzheimer's Type

Phase 3

Completed

• Conditions: Alzheimer Disease

• Registration Number: NCT00041678
• Lead Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.

Brief Summary

The purpose of this study is to learn if aripiprazole is safe and effective in the treatment of psychosis associated with dementia of the Alzheimer's type.

Detailed Description

Not available

Study Timeline

• Study Start: 2000-01
• Study First Submitted: 2002-07-12
• Study First Submitted QC: 2002-07-12
• Study First Posted: 2002-07-15
• Primary Completion: 2003-03
• Study Completion: 2003-03
• Status Verified: 2007-09
• Last Update Submitted: 2013-11-07
• Last Update Posted: 2013-11-11

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

• Institutionalized patients with Alzheimer's Disease

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: Not specified

Trial Locations

Locations (1)

Local Institution; 🇺🇸 Milwaukee, Wisconsin, United States